COVID-19

The Burden of All-Cause Mortality Following Influenza-Associated Hospitalizations | Initial Effectiveness of mRNA-1273 against SARS-CoV-2 Infection | 2024 Update of the RECOVER-Adult Long COVID Research Index | Real-world Effectiveness and Causal Mediation Study of BNT162b2 |
Personality and Neuropsychiatric Symptoms in Individuals Diagnosed with Long COVID | Post-COVID Condition Risk Factors and Symptom Clusters

BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age | Post-acute Sequelae of COVID-19 in Cancer Patients: Two Cohorts in UK and Hong Kong

Trial Stops Enrollment after Tpoxx Fails to Speed Clade 2 Mpox Healing or Pain Relief | Relative Effectiveness of Homologous NVX-CoV2373 and BNT162b2 COVID-19 Vaccinations in South Korea

Estimated Effectiveness of Influenza Vaccines | Benefit of Early Oseltamivir Therapy for Adults | Maternal Infection of SARS-CoV-2 | The Effect of Pre-COVID and Post-COVID Vaccination |
Delayed Induction of Noninflammatory SARS-CoV-2 Spike-Specific IgG4 Antibodies | Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations |
Remdesivir Effectiveness in Reducing the Risk of 30-day Readmission |
Transcutaneous Electrical Nerve Stimulation for Fibromyalgia-like Syndrome | Mitigating the Risks of Post-acute Sequelae of SARS-CoV-2 Infection | Measurement of Circulating Viral Antigens Post-SARS-CoV-2 Infection

Association between Use of a Voluntary Isolation Centre and Reduced Household SARS-CoV-2 Transmission |
Risks of SARS-CoV-2 JN.1 Infection and COVID-19–Associated Emergency Department Visits | Real Clinical Effectiveness of Molnupiravir against 30-day Mortality | Time to Sustained Recovery Among Outpatients With COVID-19 | Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 | Remdesivir for 5 or 10 Days in Patients | Remdesivir for Treatment of COVID-19 | Neurologic Manifestations of Long COVID Disproportionately Affect Young and Middle-age Adults

Serological Evidence of Mpox Virus Infection During Peak Mpox Transmission in New York City, July to August 2022 | N95 Filtering Facepiece Respirator Reuse, Extended Use, and Filtration Efficiency | Enhanced Placental Antibody Transfer Efficiency with Longer Interval Between Maternal RSV Vaccination and Birth

Real-world Effectiveness of Nirmatrelvir-Ritonavir and Molnupiravir in Non-hospitalised Adults with Covid-19: A Population-based, Retrospective Cohort Study (sic) Cohort Study | Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated with Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial |
Post-acute Sequelae of SARS-CoV-2 Cardiovascular Symptoms are Associated with Trace-level Cytokines that Affect Cardiomyocyte Function

Symptoms Six Weeks After COVID-19 are Reduced Among US Health Care Personnel Receiving Additional Vaccine Doses During the Omicron Period, December 2021–April 2022 |
Microbial Dynamics and Pulmonary Immune Responses in COVID-19 Secondary Bacterial Pneumonia |
Long-Term Risk of Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19

Repeated COVID-19 mRNA-based Vaccination Contributes to SARS-CoV-2 Neutralizing Antibody Responses in the Mucosa |
SARS-CoV-2 XBB.1.5 mRNA Booster Vaccination Elicits Limited Mucosal Immunity | Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021–2022 | Nirmatrelvir Plus Ritonavir Reduces COVID-19 Hospitalization and Prevents Long COVID in Adult Outpatients |
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo – The ACTIV-6 Randomized Clinical Trial | Clinical and Functional Assessment of SARS-CoV-2 Sequelae among Young Marines – A Panel Study

The Risk of SARS-CoV-2 Transmission in Community Indoor Settings |
Relative Effectiveness of the NVX-CoV2373 Vaccine Compared With the BNT162b2 Vaccine in Adolescents |
Viral and Symptom Rebound Following Anti-SARS-CoV-2 Monoclonal Antibody Therapy in a Randomized Placebo-controlled Trial |
The Importance of Including Long COVID Outcomes When Developing Novel Treatments for Acute COVID-19 | The Persistence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) after SARS-CoV-2 Infection